Forecasting Survival Probabilities After Radiotherapy of Metastatic Epidural Spinal Cord Compression from Colorectal Cancer in the Elderly

Standard

Forecasting Survival Probabilities After Radiotherapy of Metastatic Epidural Spinal Cord Compression from Colorectal Cancer in the Elderly. / Rades, Dirk; Bartscht, Tobias; Janssen, Stefan; Bajrovic, Amira; Segedin, Barbara; Schild, Steven E.

In: ANTICANCER RES, Vol. 36, No. 4, 04.2016, p. 1829-33.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

Rades, D, Bartscht, T, Janssen, S, Bajrovic, A, Segedin, B & Schild, SE 2016, 'Forecasting Survival Probabilities After Radiotherapy of Metastatic Epidural Spinal Cord Compression from Colorectal Cancer in the Elderly', ANTICANCER RES, vol. 36, no. 4, pp. 1829-33.

APA

Rades, D., Bartscht, T., Janssen, S., Bajrovic, A., Segedin, B., & Schild, S. E. (2016). Forecasting Survival Probabilities After Radiotherapy of Metastatic Epidural Spinal Cord Compression from Colorectal Cancer in the Elderly. ANTICANCER RES, 36(4), 1829-33.

Vancouver

Bibtex

@article{873f494820644bd1b604ddad9b77ac8f,
title = "Forecasting Survival Probabilities After Radiotherapy of Metastatic Epidural Spinal Cord Compression from Colorectal Cancer in the Elderly",
abstract = "AIM: To develop a tool forecasting survival of elderly patients with metastatic epidural spinal cord compression (MESCC) from colorectal cancer (CRC).PATIENTS AND METHODS: Fifty-seven patients were retrospectively evaluated. Eleven characteristics were investigated for survival. Independent characteristics were used for the tool. Scores were obtained from dividing 6-month survival rates by 10. From summing these points, patient scores were obtained.RESULTS: On survival analysis (Cox regression model), organ metastases (p=0.006), performance status (p<0.001), pre-radiotherapy walking ability (p<0.001) and the dynamic of developing motor weakness (p=0.033) were significant factors affecting survival and were incorporated into the tool. Possible patient scores were 5, 9, 10, 13, 14, 16, 20 or 24 points. Three groups were created with scores of 5-10, 13-16 and 20-24 points, with 6-month survival rates of 4%, 23% and 79%, respectively (p<0.001).CONCLUSION: By applying this tool, it is possible to forecast the survival of elderly patients experiencing MESCC from CRC, which is important for optimal treatment personalization.",
keywords = "Aged, Colorectal Neoplasms, Female, Humans, Male, Motor Activity, Prognosis, Proportional Hazards Models, Spinal Cord Compression, Spinal Neoplasms, Journal Article",
author = "Dirk Rades and Tobias Bartscht and Stefan Janssen and Amira Bajrovic and Barbara Segedin and Schild, {Steven E}",
note = "Copyright{\textcopyright} 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.",
year = "2016",
month = apr,
language = "English",
volume = "36",
pages = "1829--33",
journal = "ANTICANCER RES",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4",

}

RIS

TY - JOUR

T1 - Forecasting Survival Probabilities After Radiotherapy of Metastatic Epidural Spinal Cord Compression from Colorectal Cancer in the Elderly

AU - Rades, Dirk

AU - Bartscht, Tobias

AU - Janssen, Stefan

AU - Bajrovic, Amira

AU - Segedin, Barbara

AU - Schild, Steven E

N1 - Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.

PY - 2016/4

Y1 - 2016/4

N2 - AIM: To develop a tool forecasting survival of elderly patients with metastatic epidural spinal cord compression (MESCC) from colorectal cancer (CRC).PATIENTS AND METHODS: Fifty-seven patients were retrospectively evaluated. Eleven characteristics were investigated for survival. Independent characteristics were used for the tool. Scores were obtained from dividing 6-month survival rates by 10. From summing these points, patient scores were obtained.RESULTS: On survival analysis (Cox regression model), organ metastases (p=0.006), performance status (p<0.001), pre-radiotherapy walking ability (p<0.001) and the dynamic of developing motor weakness (p=0.033) were significant factors affecting survival and were incorporated into the tool. Possible patient scores were 5, 9, 10, 13, 14, 16, 20 or 24 points. Three groups were created with scores of 5-10, 13-16 and 20-24 points, with 6-month survival rates of 4%, 23% and 79%, respectively (p<0.001).CONCLUSION: By applying this tool, it is possible to forecast the survival of elderly patients experiencing MESCC from CRC, which is important for optimal treatment personalization.

AB - AIM: To develop a tool forecasting survival of elderly patients with metastatic epidural spinal cord compression (MESCC) from colorectal cancer (CRC).PATIENTS AND METHODS: Fifty-seven patients were retrospectively evaluated. Eleven characteristics were investigated for survival. Independent characteristics were used for the tool. Scores were obtained from dividing 6-month survival rates by 10. From summing these points, patient scores were obtained.RESULTS: On survival analysis (Cox regression model), organ metastases (p=0.006), performance status (p<0.001), pre-radiotherapy walking ability (p<0.001) and the dynamic of developing motor weakness (p=0.033) were significant factors affecting survival and were incorporated into the tool. Possible patient scores were 5, 9, 10, 13, 14, 16, 20 or 24 points. Three groups were created with scores of 5-10, 13-16 and 20-24 points, with 6-month survival rates of 4%, 23% and 79%, respectively (p<0.001).CONCLUSION: By applying this tool, it is possible to forecast the survival of elderly patients experiencing MESCC from CRC, which is important for optimal treatment personalization.

KW - Aged

KW - Colorectal Neoplasms

KW - Female

KW - Humans

KW - Male

KW - Motor Activity

KW - Prognosis

KW - Proportional Hazards Models

KW - Spinal Cord Compression

KW - Spinal Neoplasms

KW - Journal Article

M3 - SCORING: Journal article

C2 - 27069166

VL - 36

SP - 1829

EP - 1833

JO - ANTICANCER RES

JF - ANTICANCER RES

SN - 0250-7005

IS - 4

ER -